483
Gemini Pharmaceuticals, Inc.FDA 483 - Gemini Pharmaceuticals, Inc. - July 26, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Gemini Pharmaceuticals, Inc. in Commack, NY, revealed a significant deficiency in their manufacturing processes. The firm failed to verify that finished batches of dietary supplements met product specifications for identity, purity, strength, and composition. This was specifically noted by the absence of finished product testing for several dietary supplement products.
Open in Dashboard
ID · ece92446-1406-489e-aeac-8758665dd9f7